In the fully adjusted model, decreased adiponectin levels were still independently associated with the risk of metabolic syndrome in chronic kidney disease patients [adiponectin, 1 μg/mL increase, odds ratio (OR), 95% confidence interval (CI) = 0.956 (0.937–0.976), P < 0.001]. This evidence concerns the gene ADIPOQ and metabolic syndrome.